SIRPA and neoplasm: Studies have confirmed that IgG inhibition of CD47-SIRPα interaction in vivo and in vitro significantly enhances tumor cell antibody-dependent cell phagocytosis (ADCP) and cytotoxicity (ADCC) and enhances tumor cell neutrophil phagocytosis [49].